Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

BACKGROUND: Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adults (18-55 years) with attention-deficit/hyperactivity disorder (ADHD) using the simulated adult workplace environment. METHODS: After open-label dose optimization (4-week) with LDX, 30-70 mg/d, subje...

Descripción completa

Detalles Bibliográficos
Autores principales: Wigal, Timothy, Brams, Matthew, Gasior, Maria, Gao, Joseph, Squires, Liza, Giblin, John
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908054/
https://www.ncbi.nlm.nih.gov/pubmed/20576091
http://dx.doi.org/10.1186/1744-9081-6-34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908054/
https://www.ncbi.nlm.nih.gov/pubmed/20576091
http://dx.doi.org/10.1186/1744-9081-6-34

Ejemplares similares